NEW YORK & CHICAGO--(BUSINESS WIRE)--The debut of the US's first biosimilar drug this week could mark the beginning of a gradual conversion for the domestic pharmaceutical drug market as biosimilars begin to take share from their reference biologics, according to Fitch Ratings. Significant variance is possible in predicting the size of the US biosimilar market at this early stage, given that only one product is currently in the market and sizable challenges could slow the growth of biosimilars.
| < Prev | Next > |
|---|
